Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14 Felber LM, Kündig C, Borgońo CA, Chagas JR, Tasinato A, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D, Cloutier SM (2006) FEBS J (in press)
Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells Fattah OM, Cloutier SM, Kündig C, Felber LM, Gygi CM, Jichlinski P, Leisinger HJ, Gauthier E, Mach JP, Deperthes D (2006) Int J Cancer (in press).
Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Felber LM, Borgońo CA, Cloutier SM, Kündig C, Kishi T, Chagas JR, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D (2005) Biol Chem, 386:291-8
Profiling of proteolytic activities secreted by cancer cells using phage display substrate technology Cloutier SM, Kundig C, Gygi CM, Jichlinski P, Leisinger HJ, Deperthes D. (2004) Tumour Biol, 25:24-30
Evaluation of the CFP-substrate-YFP system for protease studies: advantages and limitations Felber LM, Cloutier SM, Kundig C, Kishi T, Brossard V, Jichlinski P, Leisinger HJ, Deperthes D. (2004) Biotechniques, 36:878-85
Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates Cloutier SM, Kundig C, Felber LM, Fattah OM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ, Deperthes D. (2004) Eur J Biochem, 271:607-13
Phage display substrate: a blind method for determining protease specificity Deperthes D. (2002) Biol Chem, 383:1107-12
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology Cloutier SM, Chagas JR, Mach JP, Gygi CM, Leisinger HJ, Deperthes D. (2002) Eur J Biochem, 269:2747-54.
